Ticker Details
Voyager Therapeutics, Inc. Voyager Therapeutics Inc in collaboration with Genzyme, conducts research and development work to develop therapies for the treatment of central nervous system disorders. It targets diseases such as Parkinson's, Alzheimer's Huntington's.
IPO Date:	November 11, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$194.04M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.32 | 3.09%
Avg Daily Range (30 D):	$0.10 | 2.58%
Avg Daily Range (90 D):	$0.11 | 2.60%

Institutional Daily Volume
Avg Daily Volume:	.48M
Avg Daily Volume (30 D):	.59M
Avg Daily Volume (90 D):	.47M

Trade Size
Avg Trade Size (Sh.):	127
Avg Trade Size (Sh.) (30 D):	100
Avg Trade Size (Sh.) (90 D):	87

Institutional Trades
Total Institutional Trades:	574
Avg Institutional Trade:	$1.4M
Avg Institutional Trade (30 D):	$2.12M
Avg Institutional Trade (90 D):	$1.46M
Avg Institutional Trade Volume:	.12M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.68M
Avg Closing Trade (30 D):	$.78M
Avg Closing Trade (90 D):	$.82M
Avg Closing Volume:	139.94K

News

Nov 25, 2025 @ 5:22 PM J&J Halts Alzheimer's Trial After Drug Fails To Sl... Source: Vandana Singh

Jul 16, 2025 @ 11:00 AM Voyager Adds Fourth Wholly-Owned Alzheimer’... Source: Voyager Therapeutics

May 15, 2025 @ 11:00 AM Voyager Demonstrates ALPL Receptor-Mediated Blood-... Source: N/A

Mar 31, 2025 @ 11:00 AM Voyager Presents Robust Preclinical Data from Tau ... Source: N/A

Mar 11, 2025 @ 8:01 PM Voyager Reports Fourth Quarter and Full Year 2024 ... Source: N/A

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-2.17	$-.47	$-.57
Diluted EPS	$-2.17	$-.47	$-.57
Revenue	$31.32M	$13.37M	$5.2M
Gross Profit
Net Income / Loss	$-126.78M	$-27.89M	$-33.38M
Operating Income / Loss	$-140.21M	$-30.59M	$-36.63M
Cost of Revenue
Net Cash Flow	$-64.66M	$3.93M	$-30.82M
PE Ratio